• Aluminium pouches with a Microwell Plate coated with monoclonal antibody to rat GM-CSF (8X12)
• 2 vials rat GM-CSF Standard lyophilized, 500 pg/ml upon reconstitution
• 2 vials concentrated Biotin-Conjugate anti-rat GM-CSF monoclonal antibody
• 2 vials Streptavidin-HRP solution
• 1 bottle Standard /sample Diluent
• 1 bottle Biotin-Conjugate antibody Diluent
• 1 bottle Streptavidin-HRP Diluent
• 1 bottle Wash Buffer Concentrate 20x (PBS with 1% Tween-20)
• 1 vial Substrate Solution
• 1 vial Stop Solution
• 4 pieces Adhesive Films
• package insert

GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocytemacrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3-5). It shows clinical effectiveness in ameliorating chemotherapyinduced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled αhelices(8-10). Mature rat GM-CSF shares 56-69% amino acid sequence identity with canine, feline, human, mouse, and porcine GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF Rα/CD116 and the signal transducing common β chain (CD131) which is also a component of the highaffinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF Rα (13). Rat GM-CSF is active on mouse cells, although mouse GM-CSF is only weakly active on rat cells (14, 15).

MartinezMoczygemba,M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.

Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.

Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.

Cao, Y. (2007) J. Clin. Invest. 117:2362.

Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.

Heuser, M. et al. (2007) Semin. Hematol. 44:148.

Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.

Kaushansky, K. et al. (1992) Biochemistry 31:1881.

Diederichs, K. et al. (1991) Science 254:1779.

Smith, L.R. et al. (1994) Immunogenetics 39:80.

OnettoPothier,N. et al. (1990) Blood 75:59.

Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655.

Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.

Oaks, M.K. et al. (1995) J. Interferon Cytokine Res. 15:1095.

Vandenabeele, P. et al. (1990) Lymphokine Res. 9:381.